Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017 (2017), Article ID 6216205, 8 pages
https://doi.org/10.1155/2017/6216205
Research Article

Synergistic Effect of the MTHFR C677T and EPHX2 G860A Polymorphism on the Increased Risk of Ischemic Stroke in Chinese Type 2 Diabetic Patients

1Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China
3Beijing Key Lab Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing, China
4Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China

Correspondence should be addressed to Yongtong Cao; moc.anis@29gnotgnoyoac and Ping Li; moc.361@5768pl

Received 13 January 2017; Revised 14 February 2017; Accepted 7 March 2017; Published 20 March 2017

Academic Editor: Tim J. Schulz

Copyright © 2017 Liang Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. International Diabetes Federation, IDF Diabetes Atlas, 7th edition, 2016, http://www.idf.org/diabetesatlas.
  2. Y. Xu, L. Wang, J. He et al., “Prevalence and control of diabetes in Chinese adults,” JAMA, vol. 310, no. 9, pp. 948–959, 2013. View at Publisher · View at Google Scholar
  3. P. Harmsen, G. Lapas, A. Rosengren, and L. Wilhelmsen, “Long-term risk factors for stroke: twenty-eight years of follow-up of 7457 middle-aged men in Göteborg, Sweden,” Stroke, vol. 37, no. 7, pp. 1663–1667, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. T. M. E. Davis, H. Millns, I. M. Stratton, R. R. Holman, R. C. Turner, and P. Bassett, “Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29,” Archives of Internal Medicine, vol. 159, no. 10, pp. 1097–1103, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. R. C. W. Ma and J. C. N. Chan, “Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States,” Annals of the New York Academy of Sciences, vol. 1281, no. 1, pp. 64–91, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Bak, D. Gaist, S. H. Sindrup, A. Skytthe, and K. Christensen, “Genetic liability in stroke: a long-term follow-up study of Danish twins,” Stroke, vol. 33, no. 3, pp. 769–774, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. W. Eikelboom, G. J. Hankey, S. S. Anand, E. Lofthouse, N. Staples, and R. I. Baker, “Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke,” Stroke, vol. 31, no. 5, pp. 1069–1075, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. W. Wang, Y. Wang, F. Gong, W. Zhu, and S. Fu, “MTHFR C677T polymorphism and risk of congenital heart defects: evidence from 29 case-control and TDT studies,” PLoS ONE, vol. 8, no. 3, Article ID e58041, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Frosst, H. J. Blom, R. Milos et al., “A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase,” Nature Genetics, vol. 10, no. 1, pp. 111–113, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. S. P. McIlroy, K. B. Dynan, J. T. Lawson, C. C. Patterson, and A. P. Passmore, “Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland,” Stroke, vol. 33, no. 10, pp. 2351–2356, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. T. P. They-They, S. Nadifi, M. A. Rafai, O. Battas, and I. Slassi, “Methylenehydrofolate reductase (C677T) polymorphism and large artery ischemic stroke subtypes,” Acta Neurologica Scandinavica, vol. 123, no. 2, pp. 105–110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Bentley, G. Peck, L. Smeeth, J. Whittaker, and P. Sharma, “Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants,” PLoS ONE, vol. 5, no. 2, Article ID e9136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Zhang, Y. Zhou, L. Han, H. Ji, and J. Li, “The effect of MTHFR C677T polymorphism on type 2 diabetes mellitus with vascular complications in Chinese Han population: a meta-analysis,” Endocrine Journal, vol. 61, no. 7, pp. 717–726, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. J.-Z. Sun, Y. Xu, H. Lu, and Y. Zhu, “Polymorphism of the methylenetetrahydrofolate reductase gene association with homocysteine and ischemic stroke in type 2 diabetes,” Neurology India, vol. 57, no. 5, pp. 589–593, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Yu, F. Xu, L. M. Huse et al., “Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids,” Circulation Research, vol. 87, no. 11, pp. 992–998, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Zhang, T. Otsuka, N. Sugo et al., “Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia,” Stroke, vol. 39, no. 7, pp. 2073–2078, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. J. D. Imig, X. Zhao, C. Z. Zaharis et al., “An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension,” Hypertension, vol. 46, no. 4, pp. 975–981, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. B. D. Przybyla-Zawislak, P. K. Srivastava, J. Vázquez-Matías et al., “Polymorphisms in human soluble epoxide hydrolase,” Molecular Pharmacology, vol. 64, no. 2, pp. 482–490, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. K. P. Burdon, A. B. Lehtinen, C. D. Langefeld et al., “Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study,” Diabetes and Vascular Disease Research, vol. 5, no. 2, pp. 128–134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Fornage, C. R. Lee, P. A. Doris et al., “The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke,” Human Molecular Genetics, vol. 14, no. 19, pp. 2829–2837, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Gschwendtner, S. Ripke, T. Freilinger et al., “Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans,” Stroke, vol. 39, no. 5, pp. 1593–1596, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Lee, M. Dahl, P. Grande, A. Tybjærg-Hansen, and B. G. Nordestgaard, “Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease,” Stroke, vol. 41, no. 1, pp. 27–33, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Zhang, H. Ding, J. Yan et al., “Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population,” Pharmacogenetics and Genomics, vol. 18, no. 1, pp. 45–51, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Zhang, X. Xie, Y. Chen, B. D. Hammock, W. Kong, and Y. Zhu, “Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo,” Circulation Research, vol. 110, no. 6, pp. 808–817, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. World Health Organization Department of Noncommunicable Disease Surveillance, Definition, Diagnosis and Classification of Diabetes Mellitus: Part 1: Diagnosis and Classification of Diabetes Mellitus, World Health Organization Department of Noncommunicable Disease Surveillance, Geneva, Switzerland, 1999.
  26. R. Lozano, M. Naghavi, K. Foremanet et al., “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010,” The Lancet, vol. 380, no. 9859, pp. 2095–2128, 1990. View at Google Scholar
  27. S. Sibani, B. Christensen, E. O'Ferrall et al., “Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria,” Human Mutation, vol. 15, no. 3, pp. 280–287, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Wilcken, F. Bamforth, Z. Li et al., “Geographical and ethnic variation of the 677C>T allele of 5, 10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide,” Journal of Medical Genetics, vol. 40, no. 8, pp. 619–625, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. X. Qin, J. Li, Y. Cui et al., “MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults,” Nutrition Journal, vol. 11, no. 1, article 2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Zhang, I. P. Koerner, R. Noppens et al., “Soluble epoxide hydrolase: a novel therapeutic target in stroke,” Journal of Cerebral Blood Flow and Metabolism, vol. 27, no. 12, pp. 1931–1940, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. K. L. Zuloaga, S. M. Krasnow, X. Zhu et al., “Mechanism of protection by soluble epoxide hydrolase inhibition in type 2 diabetic stroke,” PLoS ONE, vol. 9, no. 5, Article ID e97529, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. I. P. Koerner, R. Jacks, A. E. DeBarber et al., “Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury,” The Journal of Neuroscience, vol. 27, no. 17, pp. 4642–4649, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. W. Nelson, R. M. Subrahmanyan, S. A. Summers, X. Xiao, and N. J. Alkayed, “Soluble epoxide hydrolase dimerization is required for hydrolase activity,” Journal of Biological Chemistry, vol. 288, no. 11, pp. 7697–7703, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. K. S. Moshal, D. C. Zeldin, S. D. Sithu et al., “Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-κβ in hyperhomocysteinemia,” Journal of Cellular Physiology, vol. 215, no. 3, pp. 771–781, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Rutter, T. E. Moffitt, and A. Caspi, “Gene-environment interplay and psychopathology: multiple varieties but real effects,” Journal of Child Psychology and Psychiatry and Allied Disciplines, vol. 47, no. 3-4, pp. 226–261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Huo, J. Li, X. Qin et al., “Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial,” The Journal of the American Medical Association, vol. 313, no. 13, pp. 1325–1335, 2015. View at Publisher · View at Google Scholar · View at Scopus